Handelsavisen
prelaunch
Companies Healthcare 2279.HK
22
2279.HK HKEX Healthcare Facilities & Services

Yonghe Medical Group Co Ltd

HK$2,13
Open in Charts → Attach watcher ⌖
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
1,1B HKD
P/E
15,7x
EV / Rev
Div yield
4,22 %
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Yonghe Medical Group Co Ltd operates in the healthcare facilities and services industry, providing pharmaceutical and medical services to patients and healthcare institutions.

Business. Yonghe Medical Group Co Ltd (2279.HK) is a healthcare services and equipment company primarily engaged in pharmaceutical activities. The firm operates within the Healthcare Facilities & Services industry, generating revenue through service-based models. Headquartered in China, the company is listed on the Hong Kong Stock Exchange. Specific operating segments and geographic breakdowns are not disclosed in the available data.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target2,46

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
2,46
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
15,7x
P/E
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 2279.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 2279.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Yonghe Medical Group Co Ltd (2279.HK) is a healthcare services and equipment company primarily engaged in pharmaceutical activities. The firm operates within the Healthcare Facilities & Services industry, generating revenue through service-based models. Headquartered in China, the company is listed on the Hong Kong Stock Exchange. Specific operating segments and geographic breakdowns are not disclosed in the available data.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    Yonghe Medical Group Co Ltd has a market capitalization of 1.16 billion CNY, with a current market price of 2.2 CNY per share. The company has 525.22 million shares outstanding, with no dilution from preferred or convertible shares. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

    The company's profitability and return metrics are not available in the current dataset, making it difficult to compare with industry_config preferred metrics or cohort medians. Analysts have assigned a mean price target of 2.46 CNY, indicating a potential upside of 11.8% from the current market price. The mean recommendation score of 2.00 suggests a neutral outlook, with one "buy" rating and no "strong buy" or "hold" ratings.

    Geographic and segment exposure data are not disclosed in the available source documents, so revenue concentration and segment performance cannot be analyzed. The company's growth trajectory is also unclear, as no revenue history or outlook numeric deltas are provided in the dataset.

    The risk assessment indicates a low dilution potential, with no evidence of recent equity issuance or dilutive instruments in the financial snapshot. However, the absence of liquidity metrics and balance-sheet inputs limits the ability to assess credit risk or capital structure stability.

    No recent filings, transcripts, or material events are disclosed in the available source documents, so the company's recent operational or strategic developments cannot be evaluated.

    Key takeaways
    • The company has a market capitalization of 1.16 billion CNY and a current market price of 2.2 CNY per share.
    • Analysts have assigned a mean price target of 2.46 CNY, suggesting a potential upside of 11.8%.
    • No balance-sheet inputs or liquidity metrics are available, limiting the ability to assess financial risk.
    • The company has a low dilution potential, with no evidence of recent equity issuance.
    • No recent events or strategic developments are disclosed in the available data.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Annual
    ANNUALFiled 2024-03-28
    FY 2024 · Full-year highlights

    Revenue ¥1.78B, +25,8% YoY; Operating income −229,0% YoY.

    Revenue¥1.78B+25,8 % YoY
    Operating income-¥531.8M−229,0 % YoY
    Net income-¥546.4M−536,4 % YoY
    Free cash flow-¥383.2M−159,1 % YoY
    EPS
    Operating cash flow-¥17.2M+84,2 % YoY
    Financials
    Income statement
    Revenue¥1.78B
    Gross profit¥997.2M
    Operating income-¥531.8M
    Net income-¥546.4M
    Margins
    Gross margin56.1%
    Operating margin-29.9%
    Net margin-30.7%
    FCF margin-21.6%
    Balance sheet
    Total assets¥2.44B
    Total liabilities¥1.50B
    Total equity¥942.6M
    Cash & equivalents
    Long-term debt¥1.10B
    Cash flow
    Operating cash flow-¥17.2M
    CapEx-¥171.3M
    Free cash flow-¥383.2M
    SBC
    P&L flow · revenue → net income
    Revenue ¥1.78BOperating costs ¥2.31BTax ¥14.6MNet income ¥546.4M
    Highlights
    • Revenue ¥1.78B, +25,8% YoY
    • Operating income −229,0% YoY
    • Net income −536,4% YoY
    • Free cash flow −159,1% YoY
    • Net margin -30.7%

    Valuation FY

    Market price
    HK$2,13
    Market cap
    HK$1.16B
    Enterprise value
    P/E
    15.7x
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price targetHK$2,46 · Median HK$2,46
    Low HK$2,46High HK$2,46
    Operating income · consensus145,0M CNY

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    LowHK$2,46
    MeanHK$2,46
    MedianHK$2,46
    HighHK$2,46
    SpotHK$2,13
    +15.5 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Yonghe Medical Group Co Ltd Market data — financials · 2026-05-26
    • Yonghe Medical Group Co Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    2279.HKCanonical
    HKEX · HKD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2024-03-28 16:03 UTCEARNINGSAnnual results — FY 2024 Revenue CNY 1.78B · Net CNY -546.4M
    2023-03-30 17:45 UTCEARNINGSAnnual results — FY 2023 Revenue CNY 1.41B · Net CNY -85.9M
    2022-03-24 17:09 UTCEARNINGSAnnual results — FY 2022 Revenue CNY 2.17B · Net CNY 120.2M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage